Last reviewed · How we verify
VYD2311
At a glance
| Generic name | VYD2311 |
|---|---|
| Sponsor | Invivyd, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of VYD2311 for the Prevention of COVID-19 (PHASE3)
- A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VYD2311 CI brief — competitive landscape report
- VYD2311 updates RSS · CI watch RSS
- Invivyd, Inc. portfolio CI